Hospitals NHS Trust, United Kingdom Introduction: Right portal vein embolization [RPVE] may be used to increase the volume of the future liver remnant [FRL] before major hepatic resection. It is not established whether embolization of segment 4 in addition RPVE [RPVE+4] induces greater hypertrophy of the FRL. Limitations of prior studies include heterogenous populations and absence of correction for patient size. Methods: From 2010 to 2015, consecutive patients undergoing RPVE or RPVE+4 for colorectal liver metastases [CRLM]
Background: A !1-mm margin is standard for resection of colorectal liver metastases (CLM). However, R1 resection is not rare (10%-30%), and chemotherapy could mitigate its impact. The possibility of detaching CLM from vessels (R1 vascular margin) has been described. A reappraisal of R1 resection is needed. Methods: A 19-question survey regarding R1 resection for CLM was sent to hepatobiliary surgeons worldwide. Seven clinical cases were included. Results: In total, 276 surgeons from 52 countries completed the survey. Ninety percent reported a negative impact of R1 resection (74% local recurrence, 31% hepatic recurrence, and 36% survival), but 50% considered it sometimes required for resectability. Ninety-one percent of responders suggested that the impact of R1 resection is modulated by the response to chemotherapy and/or CLM characteristics. Half considered the risk of R1 resection to be an indication for preoperative chemotherapy in patients who otherwise underwent upfront resection, and 40% modified the chemotherapy regimen when the tumor response did not guarantee R0 resection. Nevertheless, 80% scheduled R1 resection for multiple bilobar CLM that responded to chemotherapy. Forty-five percent considered the vascular margin equivalent to R0 resection. However, for lesions in contact with the right hepatic vein, right hepatectomy remained the standard. Detachment from the vein was rarely considered (10%), but 27% considered detachment in the presence of multiple bilobar CLM. Conclusions: A negative margin is still standard for CLM, but R1 resection is no longer just a technical error. R1 resection should be part of the modern multidisciplinary, aggressive approach to CLM.
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The effectiveness of modern chemotherapy regimens means that colorectal liver metastases(CRLM) may no longer be detected on post-therapy cross-sectional imaging. These missing metastases(MM) represent a clinical challenge for surgeons. While microscopic tumor rests might still be present and progress if not removed, there are lesions that present complete pathological response, upon which any further treatment could only result in morbidity. Methods: We prospectively reviewed liver resections performed for CRLM at our center between 01/2012 and 12/2016, evaluating the rate of MM as well as clinical, radiological, and pathological features. Results: Liver resections were performed in 264 patients, among whom 16 presented MM, demonstrating complete pathological tumor response 12 cases(75%). Primary tumor was located more frequently in colon, being all cases synchronous metastases. Eighty-four percent of patients presented T3-T4 as primary tumor with 67% of HPB 2018, 20 (S2), S182eS294
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